Growth factor antagonists for the treatment of diabetic vascular complications

Bibliography

• MARKS HH, KRALL LP: Onset, course, prognosis and mortality in diabetes mellitus. In: Joslin's Diabetes Melli-tus. (11th Edition). Marble A, White P, Bradley RF, Krall LP (Eds.), Lea and Febiger Philadelphia, USA (1970:209–254.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Direct and indirect costs of diabetes in the United States in 1992. (1993).
   Google Scholar
• WILLIAMSON JR, CHANG K, FRANGOS M et al: Hypergly-cemic pseudohypoxia and diabetic complications. Dia-betes (1993) 42:801–813.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, CERAMI A, VLASSARA H: Advanced glyco-sylation end products in tissue and the biochemical ba-sis of diabetic complications. New Engl. J Med. (1988) 318:1315–1321.
   PubMed Web of Science ®Google Scholar
• RUDERMAN NB, WILLIAMSON JR, BROWNLEE M: Glucoseand diabetic vascular disease. FASEB j (1992) 6:2905–2914.
   PubMed Web of Science ®Google Scholar
• JENSEN PK, CHRISTIANSEN SJ, STEVEN K, PARVING HH: Strict metabolic control and renal function in the strep-tozotocin diabetic rat. Kidney Int. (1987) 31:47–51.
   PubMed Web of Science ®Google Scholar
• KERN TS, ENGERMAN RL: Arrest of glomerulopathy in diabetic dogs by improved glycaemic control. Diabe-tologia (1990) 33:522–525.
   PubMed Web of Science ®Google Scholar
• RASCH R: Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Albu-min excretion. Diabetologia (1980) 18:413–416.
   PubMed Web of Science ®Google Scholar
• CHRISTIANSEN SJ, GAMMELGAARD J, TRONIER B, SVEND-SEN PA, PARVING HH: Kidney function and size in dia-betics before and during initial insulin treatment. Kidney Int. (1982) 21:683–688.
   PubMed Web of Science ®Google Scholar
• THE DIABETES CONTROL AND COMPLICATIONS TRIALRESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mel-litus. (1993) 329:977–986.
   Google Scholar
• CAHILL GF, ETZWILER DD, FREINKEL N: 'Control' and diabetes. New Engl. J Med. (1976) 294:1004–1005.
   PubMed Web of Science ®Google Scholar
• PUGLIESE G, TILTON RG, SPEEDY A et al.: Effects of very mild versus overt diabetes on vascular haemodynam-ics and barrier function in rats. Diabetologia (1989) 32:845–857.
   PubMed Web of Science ®Google Scholar
• PUGLIESE G, TILTON RG, WILLIAMSON JR: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diab. Metab. Rev. (1991) 7:35–59.
   PubMed Web of Science ®Google Scholar
• TILTON R, CHANG K, PUGLIESE G et al. Prevention on hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes (1989) 38:1258–1270.
   PubMed Web of Science ®Google Scholar
• PUGLIESE G, TILTON R, SPEEDY A et al.: Vascular filtra-tion function in galactose-fed versus diabetic rats: the role of polyol pathway activity. Metabolism (1990) 39:690–697.
   PubMed Web of Science ®Google Scholar
• WOLF B, WILLIAMSON JR, EASOM R et al.: Diacylglycerolaccumulation and microvascular abnormalities in-duced by elevated glucose levels. J. Gin. Invest. (1991) 87:31–38.
   PubMed Web of Science ®Google Scholar
• WINEGRAD Al: Does a common mechanism induce thediverse complications of diabetes? Diabetes (1987) 36:396–406.
   PubMed Web of Science ®Google Scholar
• CRAVEN PA, CAINES MA, DERUBERTIS FR: Sequential al-terations in glomerular prostaglandin and thrombax-ane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism (1987) 36:95–103.
   PubMed Web of Science ®Google Scholar
• GREENE DA, LATTIMER S, ULBRECHT J, CARROLL P: Glucose-induced alterations in nerve metabolism: cur-rent perspective on the pathogenesis of diabetic neuro-pathy and future directions for research and therapy. Diabetes Care (1985) 8:290–299.
   PubMed Web of Science ®Google Scholar
• PFEIFER MA, SCHUMER MP, GELVER DA: Aldose reduc-tase inhibitors: the end of an era or the need for differ-ent trial designs? Diabetes (1997) 46 (Suppl. 2):S82–S89.
   Google Scholar
• TILTON RG, CHANG K, NYENGAARD JR et al.: Inhibition of sorbitol dehydrogenase: effects on vascular and neu-ral dysfunction in streptozocin-induced diabetic rats. Diabetes (1995) 44:234–242.
   PubMed Web of Science ®Google Scholar
• TILTON RG, KAWAMURA T, CHANG KC et al.: Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J. Clin. Invest. (1997) 99:2192–2202.
   PubMed Web of Science ®Google Scholar
• FRANK RN, AMIN R, KENNEDY A, HOHMAN TC: An aldose reductase inhibitor and aminoguanidine prevent vas-cular endothelial growth factor expression in rats with long-term galactosemia. Arch. OphthalmoL (1997) 115:1036–1047.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AM, HORI O, BRETT J et al.: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. (1994) 14:1521–1528.
   Google Scholar
• CHAPPEY O, DOSQUET C, WAUTIER M-P, WAUTIER J-L: Advanced glycation end products, oxidant stress and vascular lesions. Eur. j Clin. Invest. (1997) 27:97–108.
   PubMed Web of Science ®Google Scholar
• YANG CW, VLASSARA H, PETEN EP et al.: Advanced glyca-tion end products up-regulate gene expression found in diabetic glomerular disease. Proc. Natl. Acad. Sci. USA (1994) 91:9436–9440.
   PubMed Web of Science ®Google Scholar
• ESPOSITO C, GERLACH H, BRETT J, STERN D, VLASSARA H: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased mono-layer permeability and modulation of cell surface co-agulant properties. J. Exp. Med. (1989) 170:1387–1407.
   PubMed Web of Science ®Google Scholar
• HIGASHI T, SANO H, SAISHOJI T et al.: The receptor of ad-vanced glycation end products mediates the chemo-taxis of rabbit smooth muscle cells. Diabetes (1997) 46:463–472.
   PubMed Web of Science ®Google Scholar
• FREDMAN J, PAULY RR, STERN D et al.: Advanced glyca-tion endproducts interacting with their receptors acti-vate vascular smooth muscle cells: induction of chemoattractants for smooth muscle cells and mono-cytes. Circulation (1994) 90:1–291.
   PubMedGoogle Scholar
• TEZUKA M, KOYAMA N, MORISAKI N et al: Angiogenic ef-fects of advanced glycation end products of the Mail-lard reaction on cultured human umbilical cord vein endothelial cells. Biochem. Biophys. Res. Commun. (1993) 193:674–680.
   PubMed Web of Science ®Google Scholar
• KUROKI M, VOEST EE, AMANO S et al.: Reactive oxygenintermediates increase vascular endothelial growth factor expression in vitro and in vivo. J. Clin. Invest. (1996) 98:1667–1675.
   PubMed Web of Science ®Google Scholar
• WILLIAMS B: Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J. Hypertens. (1995) 13:477–486.
   PubMed Web of Science ®Google Scholar
• KING GL: The role of hyperglycaemia and hyperinsu-linaemia in causing vascular dysfunction in diabetes. Ann. Med. (1996) 28:427–432.
   PubMed Web of Science ®Google Scholar
• XIA P, AIELLO L, ISHII H et al.: Characterization of vascu-lar endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. (1996) 98:2018–2026.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, BURSELL S-E, CLERMONT A et al.: Vascular en-dothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective 13 isoform-selective inhibitor. Diabe-tes (1997) 46:1473–1480.
   PubMed Web of Science ®Google Scholar
• ISHII H, JIROUSEK M, KOYA D et al.: Amelioration of vas-cular dysfunction in diabetic rats by an oral PKC 13 in-hibitor. Science (1996) 272:728–731.
   PubMed Web of Science ®Google Scholar
• SHARP PS: Growth factors in the pathogenesis of dia-betic retinopathy. Diab. Rev (1995) 3:164–176.
   Google Scholar
• SERRI O, RENIER G: Intervention in diabetic vascular dis-ease by modulation of growth factors. Metabolism (1995) 44:83–90.
   PubMed Web of Science ®Google Scholar
• MILLER JW, ADAMIS SP, AIELLO LP: Vascular endothelialgrowth factor in ocular neovascularization and prolif-erative diabetic retinopathy. Diab. Met. Rev. (1997) 13:37–50.
   PubMed Web of Science ®Google Scholar
• ADAMIS A, MILLER J, BERNAL M-T et al.: Increased vascu-lar endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Oph-thalmol (1994) 118W0:445–450.
   Google Scholar
• AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endo-thelial growth factor in ocular fluid of patients with dia-betic retinopathy and other retinal disorders. New Engl. J Med. (1994) 331:1480–1487.
   PubMed Web of Science ®Google Scholar
• AMIN R, FRANK R, KENNEDY A et al.: Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest. Ophthalmol Vis. Sci. (1997) 38:36–47.
   PubMed Web of Science ®Google Scholar
• BOULTON M, GREGOR Z, MCLEOD D et al.: Intravitrealgrowth factors in proliferative diabetic retinopathy: correlation with neovascular activity and gylcaemic management. Br. J. Ophthalmol (1997) 81:228–233.
   PubMed Web of Science ®Google Scholar
• DOREY CK, AOUIDIDI S, REYNAUD X, DVORAK HF, BROWN LF: Correlation of vascular permeability fac-tor/vascular endothelial growth factor with extrareti-nal neovascularization in the rat. Arch. Ophthalmol. (1996) 114:1210–1217.
   PubMed Web of Science ®Google Scholar
• INABA T, ISHIBASHI S, GOTODA T et al: Enhanced ex-pression of platelet-derived growth factor-6 receptor by high glucose. Diabetes (1996) 45:507–512.
   PubMed Web of Science ®Google Scholar
• LEROITH D, WERNER H, PHILLIP M, ROBERTS CT, Jr.: The role of insulin-like growth factors in diabetic kidney disease. Am. J. Kidney Dis. (1993) 22:722–726.
   Google Scholar
• LOWE WL, FLORKIEWICZ RZ, YOREK MA, SPANHEIMERRG, ALBRECHT BN: Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism (1995) 44:1038–1045.
   PubMed Web of Science ®Google Scholar
• OHSATA M, HAYASHI H, OSHIMA K, KOJI T, NAKANE P: Insitu localization of basic fibroblast growth factor pro-tein and mRNA in the retina. Ophthal Res. (1997) 29:24–30.
   PubMed Web of Science ®Google Scholar
• PEER J, FOLBERG R, ITIN A eta].: Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br. J. Ophthalmol. (1996) 80:241–245.
   Google Scholar
• MERENMIES J, PARADA LF, HENKEMEYER M: Receptor ty-rosine kinase signaling in vascular development. Cell Growth Diff (1997) 8:3–10.
   PubMedGoogle Scholar
• GULER HP, SCHMID C, ZAPF J et al.: Effects of recombi-nant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc. Nati Acad. Sci. USA (1989) 86:2868–2872.
   PubMed Web of Science ®Google Scholar
• DOT T, STRIKER LJ, QUAIFE C et al.: Progressive glomeru-losclerosis develops in transgenic mice chronically ex-pressing growth hormone and growth hormone releasing factor but not in those expressing insulin-like growth factor-1. Am. J. Pathol (1988) 131:398–403.
   PubMed Web of Science ®Google Scholar
• SMITH LEH, KOPCHICK JJ, CHEN W et al.: Essential role of growth hormone in ischemia-induced retinal neovas-cularization. Science (1997) 276:1706–1709.
   PubMed Web of Science ®Google Scholar
• FLYVBJERG A, FRYSTYK J, THORLACIUS-USSING O et al.:Somatostatin analogue administration prevents in-crease in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabe-tologia (1989) 32:261–265.
   PubMed Web of Science ®Google Scholar
• GRANT MB, MAMES RN, FITZGERALD C et al.: Insulin-like growth factor 1 acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fi-broblast growth factor. Diabetologia (1993) 36:282–291.
   PubMed Web of Science ®Google Scholar
• PUNGLIA RS, LU M, HSU J et al.: Regulation of vascular en-dothelial growth factor expression by insulin-like growth factor I. Diabetes (1997) 46:1619–1626.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA H, DECKERT T: Central role of TGF-13 in the pathogenesis of diabetic nephropathy and macrovas-cular complications: a hypothesis. Diab. Med. (1996) 13:313–320.
   PubMed Web of Science ®Google Scholar
• IGNOTZ R, MASSEGUE J: Cell adhesion protein as targetsfor transforming growth factor 3 action. Cell (1987) 51:189–197.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, FUJIWARA Y, UEDA N et al.: Glomerulosclerosisinduced by in vivo transfection of transforming growth factor-I3 or platelet-derived growth factor gene in the rat kidney. J. Clin. Invest. (1993) 92:2597–2601.
   PubMed Web of Science ®Google Scholar
• ZIYADEH FN, SHARMA K, ERICKSEN M, WOLF G: Stimula-tion of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth fac - tor-13. j Clin. Invest. (1994) 93:536–542.
   PubMed Web of Science ®Google Scholar
• BEISSWENGER PJ, MOORE LL, BRINCK-JOHNSEN T, CUR-PHEY T: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early dia-betic nephropathy. j Clin. Invest. (1993) 92:212–217.
   PubMed Web of Science ®Google Scholar
• KAGAMI S, BORDER WA, MILLER DE, NOBLE NA: Angio-tensin II stimulates extracellular matrix protein syn-thesis through induction of transforming growth factor-6 expression in rat glomerular mesangial cells. J. Clin. Invest. (1994) 93:2431–2437.
   PubMed Web of Science ®Google Scholar
• SIVALINGAM A, KENNEY J, BROWN GC, BENSON WE, DONOSO L: Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retino-pathy. Arch. Ophthalmol. (1990) 108:869–872.
   PubMed Web of Science ®Google Scholar
• TAIPALE J, KESKI-OJA J: Growth factors in the extracellu-lar matrix. FASEB J. (1997) 11:51–59.
   PubMed Web of Science ®Google Scholar
• ADAMIS A: Inhibition of VEGF prevents ocular neovas-cularization in a non-human primate. Arch. Ophthalmol. (1996) 114:66–71.
   PubMed Web of Science ®Google Scholar
• AIELLO LP: Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc. Natl. Acad. Sci. USA (1995) 92:10457–10461.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, PIERCE EA, FOLEY ED et al.: Suppression of retinal neovascularization in vivo by inhibition of vas-cular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA (1995) 92:10457–10461.
   PubMed Web of Science ®Google Scholar
• NYENGAARD JR, RASCH R: The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia (1993) 36:189–194.
   PubMed Web of Science ®Google Scholar
• CAVALLINI L, VALENTE M, RIGOBELLO MP: The protec-tive action of pyruvate on recovery of ischemic rat heart: comparison with other oxidizable substrates. J. Mol. Cell Cardiol (1990) 22:143–154.
   PubMed Web of Science ®Google Scholar
• LADOUX A, FRELIN C: Hypoxia is a strong inducer of vas-cular endothelial growth factor mRNA expression in the heart. Biochem. Biophys. Res. Commun. (1993) 195:1005–1010.
   PubMed Web of Science ®Google Scholar
• DVORAK HF, BROWN LF, DETMAR M, DVORAK AM: Vas-cular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angio-genesis. Am. J. Pathol (1995) 146:1029–1039.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, NORTHRUP JM, KEYT BA, TAKAGI H, IWA-MOTO MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. (1995) 113:1538–1544.
   PubMed Web of Science ®Google Scholar
• SONE S, KAWAKAMI Y, OKUDA Y et al.: Vascular endothe-lial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose depri-vation in cultured bovine retinal pigmented epithelial cells. Biochem. Biophys. Res. Comm. (1996) 221:193–198.
   PubMed Web of Science ®Google Scholar
• BICKNELL R, HARRIS AL: Mechanisms and therapeutic implications of angiogenesis. Curr. Opin. Oncol (1996) 8:60–65.
   PubMed Web of Science ®Google Scholar
• PEPPER MS: Manipulating angiogenesis: from basic sci-ence to the bedside. Arterioscler. Thromb. Vasc. (1997) 17:605–619.
   PubMed Web of Science ®Google Scholar
• PLUDA JM: Tumor-associated angiogenesis: mecha-nisms, clinical implications, and therapeutic strategies. Sem. Oncol. (1997) 24:203–218.
   PubMed Web of Science ®Google Scholar
• FOX SB, HARRIS AL: Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest. New Drugs (1997) 15:15–28.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS: The preclinical evaluation of angiogenesis inhibitors. Invest. New Drugs (1997) 15:5–13.
   Google Scholar
• KENDALL RL, THOMAS KA: Inhibition of vascular endo-thelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Nati Acad. Sci. USA (1993) 90:10705–10709.
   PubMed Web of Science ®Google Scholar
• MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for Tie2 that dis-rupts in vivo angiogenesis. Science (1997) 277:55–60.
   PubMed Web of Science ®Google Scholar